RecruitingPhase 2NCT06716658

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Studying Aggressive NK-cell leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Intervention
JAK1 Inhibitor(drug)
Enrollment
48 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2028

Study locations (2)

Collaborators

Tianjin First Central Hospital · The First Affiliated Hospital of Air Force Medicial University · The First Hospital of Jilin University · The First Affiliated Hospital of Nanchang University · Henan Cancer Hospital · Second Xiangya Hospital of Central South University · Tongji Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06716658 on ClinicalTrials.gov

Other trials for Aggressive NK-cell leukemia

Additional recruiting or active studies for the same condition.

See all trials for Aggressive NK-cell leukemia →

← Back to all trials